HMGvsKissPeptin-10

Human Menopausal Gonadotropin is a purified urinary extract containing both follicle-stimulating hormone (FSH) and luteinizing hormone (LH) activity, sourced from the urine of postmenopausal women. After menopause, the loss of ovarian negative feedback (estradiol and inhibin) results in dramatically elevated pituitary gonadotropin secretion — FSH and LH levels rise 10-20 fold, providing a natural source of these hormones for pharmaceutical extraction.

The FSH component binds to FSH receptors (FSHR) on Sertoli cells in males and granulosa cells in females. FSHR is a Gs-coupled GPCR that activates cAMP/PKA signaling, driving the expression of genes essential for gametogenesis. In males, FSH-stimulated Sertoli cells produce androgen-binding protein (which concentrates testosterone locally), inhibin B (which provides negative feedback to the pituitary), and multiple growth factors that support spermatogonial proliferation and differentiation through the stages of spermatogenesis. In females, FSH drives follicular development — stimulating granulosa cell proliferation, estradiol synthesis via aromatase induction, and the growth of ovarian follicles from the pre-antral to the pre-ovulatory stage.

The LH component acts on Leydig cells in males (stimulating testosterone production via the LHCGR/cAMP/StAR steroidogenic pathway) and on theca cells in females (stimulating androgen precursor production that granulosa cells convert to estradiol). In females undergoing fertility treatment, the LH component is also critical for final oocyte maturation and ovulation triggering. The combination of both FSH and LH activity in HMG provides more complete gonadal stimulation than either gonadotropin alone — FSH drives the cellular proliferation and maturation processes while LH provides the steroidogenic and final maturation signals. This dual activity is why HMG is sometimes preferred over purified FSH preparations in certain fertility protocols, particularly in hypogonadotropic patients who lack endogenous LH.

KissPeptin-10 is the shortest bioactive fragment of the kisspeptin family, derived from the 145-amino-acid precursor protein encoded by the KISS1 gene. The kisspeptin system was identified as the master upstream regulator of the hypothalamic-pituitary-gonadal (HPG) axis when loss-of-function mutations in its receptor (KISS1R/GPR54) were found to cause hypogonadotropic hypogonadism — complete failure of puberty and reproductive function.

Kisspeptin-10 binds to KISS1R (formerly GPR54), a Gq/11-coupled GPCR expressed predominantly on GnRH neurons in the hypothalamus, specifically in two key nuclei: the arcuate nucleus (ARC) and the anteroventral periventricular nucleus (AVPV). KISS1R activation stimulates phospholipase C, generating IP3 and DAG, which raise intracellular calcium and activate protein kinase C in GnRH neurons. This depolarizes the neurons and triggers GnRH release into the hypophyseal portal system, which then stimulates FSH and LH secretion from anterior pituitary gonadotrophs.

What makes kisspeptin extraordinary is its position at the very apex of the reproductive hormone cascade. It sits upstream of GnRH itself, integrating metabolic, circadian, and hormonal signals to determine when and how strongly GnRH pulses fire. Kisspeptin neurons in the ARC co-express neurokinin B and dynorphin (forming the 'KNDy' neuron population) and function as the GnRH pulse generator — the fundamental oscillator that drives pulsatile reproductive hormone secretion. Estradiol and testosterone feed back to kisspeptin neurons (not directly to GnRH neurons) to regulate the HPG axis, making kisspeptin the integration point for sex steroid feedback. This upstream position makes kisspeptin-10 a uniquely powerful tool for stimulating the entire reproductive axis from the top, with clinical potential for triggering ovulation in IVF protocols and restoring fertility in functional hypogonadism.